Drug Trial Radar · NCT05635084
A First-in-human Study of YN001 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Dec 16, 2022
Primary completion
Aug 9, 2024
Study completion Aug 9, 2024
Sponsor
- Lead sponsor
- Beijing Inno Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study in healthy adult subjects.
Conditions
- Cardiovascular Diseases
Interventions
YN001Drug
Dose ranges from 2-90mg
Placebo for YN001Drug
5% dextrose injection to mimic the YN001
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety and tolerability of intravenously administered YN001 in healthy subjects.Time frame: Up to 15 days of last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.